Navigation Links
Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference

RYE, N.Y., Sept. 21 /PRNewswire/ -- Curemark, LLC, (, a drug research and development company focused on the treatment of neurological diseases, presented at the Rodman & Renshaw Annual Global Investment Conference held September 12-15 in New York City.  The global investment conference attracted more than 5,000 investors and other attendees.  

"Curemark was one of only a handful of private companies invited to present at the conference, which included a full roster of 610 companies presenting," said Dr. Joan Fallon said, Curemark founder and CEO.  "To be able to participate was a terrific opportunity to showcase our progress, as the event was essentially a packed house."

At the conference, Fallon discussed the momentum of Curemark's drug pipeline.  CM-AT, the company's autism treatment in development, is currently in Phase III clinical trials at 13 sites nationwide and has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).  The FDA also has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of the company's compound CM-4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

Curemark's autism treatment targets enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          


Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... JERUSALEM , Nov. 30, 2015 Oramed ... company focused on the development of oral drug delivery ... investment agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of ... Oramed,s oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed ...
(Date:11/30/2015)... N.H. , Nov. 30, 2015 ... that it will feature its latest solutions for ... early identification of cancer at the Radiological Society ... Chicago from November 29 ... recent product advances including iReveal®, an automated breast ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... is one of a select few plastic surgeons in the New York City ... , SculpSure™ is the world’s first heat-induced laser treatment for fat loss in ...
(Date:11/30/2015)... ... November 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created ... web-styled transitions to wipes with blur & drop shadow options. Utilize the controls ... from one clip to the next with TransPack's easily customizable styles. , ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
Breaking Medicine News(10 mins):